Top Medical News from Across Medscape

  • Canakinumab Reduces Gout Risk Without Changing SUA LevelsCanakinumab, an interleukin 1-beta blocker, was associated with significantly lower risk for gout attacks when given quarterly, but did not change serum uric acid levels, a study has found.
  • For Stubborn COPD, Airway Ablation Bolsters Drug EffectsTargeted lung denervation appears to maximize the benefits of the anticholinergic drugs often prescribed to patients with chronic obstructive pulmonary disease (COPD), new research shows.
  • WHO: Global Efforts to End TB 'Off Track'Global efforts have averted an estimated 54 million tuberculosis deaths since 2000, but tuberculosis remains the world's deadliest infectious disease and countries are still not doing enough to end it by 2030, WHO says.

Special Report

Business of Medicine

Medscape Editor-in-Chief

  • Eric J. Topol, MD Director, Scripps Translational Science Institute; Chief Academic Officer, Scripps Health; Professor of Genomics, The Scripps Research Institute, La Jolla, California